Secondary prevention in thrombotic antiphospholipid syndrome

Lupus

Volumn 21, Issue 7, 2012, Pages 734-735

  Pengo, V ^a   Denas, G ^a   Banzato, A ^a   Bison, E ^a   Bracco, A ^a   Facchinetti, M ^b   Hoxha, A ^b   Ruffatti, A ^b  

^a Thrombosis Centre   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

antiphospholipid; drugs; prevention; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; BRAIN ISCHEMIA; CONFERENCE PAPER; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATENT FORAMEN OVALE; PRIORITY JOURNAL; SECONDARY PREVENTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84861538756     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312444773     Document Type: Conference Paper

References (10)

1. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007 ; 57: 1487-1495
2. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 ; 349: 1133-1138
3. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005 ; 3: 848-853
4. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med. 2004 ; 164: 668-673
5. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010 ; 8: 237-242
6. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005 ; 129: 72-78
7. Albers GW, Amarenco P, Donald Easton J, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008 ; 133: 630S - 669S
8. Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev 2011; [ePub ahead of print].
9. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011 ; 20: 206-218
10. Urlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002 ; 347: 969-974